Cardinal Capital Management Invests $3.46 Million in DexCom, Inc. (NASDAQ:DXCM)

Cardinal Capital Management bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 44,483 shares of the medical device company’s stock, valued at approximately $3,459,000.

A number of other large investors have also added to or reduced their stakes in DXCM. Principal Securities Inc. grew its holdings in shares of DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock valued at $316,000 after purchasing an additional 135 shares during the last quarter. Crossmark Global Holdings Inc. lifted its stake in DexCom by 1.0% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock valued at $1,259,000 after purchasing an additional 182 shares during the last quarter. GPS Wealth Strategies Group LLC boosted its position in DexCom by 13.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock valued at $123,000 after buying an additional 185 shares in the last quarter. Peterson Wealth Services grew its stake in shares of DexCom by 7.1% during the fourth quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company’s stock worth $236,000 after buying an additional 201 shares during the last quarter. Finally, Magnolia Capital Advisors LLC grew its stake in shares of DexCom by 2.6% during the fourth quarter. Magnolia Capital Advisors LLC now owns 8,198 shares of the medical device company’s stock worth $638,000 after buying an additional 210 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,342 shares of company stock valued at $3,628,069 in the last quarter. 0.30% of the stock is currently owned by company insiders.

DexCom Stock Performance

Shares of DexCom stock opened at $89.07 on Tuesday. The business has a 50-day moving average price of $82.44 and a two-hundred day moving average price of $75.49. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company has a market cap of $34.79 billion, a P/E ratio of 53.34, a PEG ratio of 2.26 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 31.40% and a net margin of 17.22%. As a group, analysts anticipate that DexCom, Inc. will post 1.69 EPS for the current year.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of research reports. Sanford C. Bernstein increased their price target on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Oppenheimer dropped their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Royal Bank of Canada cut their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Raymond James lowered their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Finally, Wells Fargo & Company raised their price objective on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $99.06.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.